Gambro is an innovator and pioneer when it comes to finding new ways to optimize PD treatment. Essential ongoing research highlights the connection between PD fluids and the preservation of residual renal function.
We have been researching the significance of Glucose Degradation Products (GDPs) within PD fluids for almost 20 years, resulting in knowledge that has changed the way the industry looks at the issue of biocompatibility within the area of PD fluids.